Video
Dr. Goldberg explains disparities in shared decision-making for prostate cancer screening
Author(s):
“We do know that for these specific racial minorities, more time and more tools need to be invested in order to have both the rates of PSA discussion and PSA testing equal to those that White men have,” says Hanan Goldberg, MD, MSc.
Video Player is loading.
Hanan Goldberg, MD, MSc, discusses the sociodemographic disparities found in his recent study on shared decision-making for prostate cancer screening, which was presented at the 74th Annual Meeting of the Northeastern Section of the American Urological Association. Goldberg is an assistant professor at SUNY Upstate Medical University in Syracuse, New York.
Related Videos
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Study results affirm effectiveness of evolving prostate cancer therapies
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
Related Content
